Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Crescent Capital BDC: Weighing a Double-Digit Yield Against Financial Strain

Andreas Sommer by Andreas Sommer
December 7, 2025
in Analysis, Bonds, Dividends
0
Crescent Capital BDC Stock
0
SHARES
13
VIEWS
Share on FacebookShare on Twitter

For income-focused investors, Crescent Capital BDC presents a compelling proposition with a dividend yield exceeding 11%. However, this substantial payout comes with significant caveats, including an unsustainable distribution model and a steep share price decline over the past year.

Market analysts express cautious optimism regarding the stock’s price potential. The consensus average price target stands at $16.38, suggesting an approximate 10% upside from recent trading levels around $14.90. Sentiment among research firms is mixed: one issues a “Strong Buy” recommendation, three advocate “Buy,” one suggests “Hold,” and another advises “Sell.”

Assessing the Dividend’s Sustainability

The primary attraction of this investment is its high quarterly distribution of $0.42 per share. The upcoming ex-dividend date is set for December 31, 2025, with payment following on January 15, 2026.

A closer examination of the dividend’s foundation reveals considerable strain. The company’s payout ratio has ranged between 171% and 188%, indicating it is distributing far more capital to shareholders than it has earned in net income. Such a practice is widely viewed as untenable over the long term.

Should investors sell immediately? Or is it worth buying Crescent Capital BDC?

Financial Performance and Valuation Metrics

The equity has faced substantial headwinds, declining nearly 24% in value over the previous twelve months. Crescent Capital BDC currently commands a market capitalization of roughly $551 million.

Key valuation and balance sheet figures present a complex picture:
* The trailing twelve-month price-to-earnings (P/E) ratio is 15.3.
* The forward-looking P/E ratio is notably lower at 9.1.
* The debt-to-equity ratio, a measure of financial leverage, is reported at 1.2.

The firm’s most recent quarterly results, released in November, fell slightly short of market expectations. Earnings per share came in at $0.46 against a forecast of $0.47, while revenue reached $41.35 million versus an anticipated $42.35 million. Despite this minor earnings miss, management has maintained its current dividend policy.

Investors considering Crescent Capital BDC must carefully balance the allure of a high current income stream against the fundamental risks posed by its excessive payout ratio and negative price momentum. The next critical date for shareholders will be the year-end ex-dividend date.

Ad

Crescent Capital BDC Stock: Buy or Sell?! New Crescent Capital BDC Analysis from February 8 delivers the answer:

The latest Crescent Capital BDC figures speak for themselves: Urgent action needed for Crescent Capital BDC investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Crescent Capital BDC: Buy or sell? Read more here...

Tags: Crescent Capital BDC
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Next Post
Ryerson Stock

Ryerson's Strategic Acquisition: Navigating Risk Amid Expansion Plans

Lynas Stock

Lynas Secures Coveted Spot Among Australia's Top 50 Listed Companies

Solana Stock

France Emerges as a Key Market for Solana Amid Regional Divergence

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com